196.10
-1.45
(-0.73%)
At close: January 10 at 3:30:38 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
761,000.00
761,000.00
1,119,000.00
1,553,000.00
1,081,000.00
Investing Cash Flow
-440,000.00
-440,000.00
-1,580,000.00
-487,000.00
-2,228,000.00
Financing Cash Flow
-308,000.00
-308,000.00
70,000.00
-1,119,000.00
1,177,000.00
End Cash Position
861,000.00
861,000.00
859,000.00
1,244,000.00
1,303,000.00
Capital Expenditure
-316,000.00
-316,000.00
-371,000.00
-493,000.00
-349,000.00
Issuance of Capital Stock
--
--
--
--
150,000.00
Issuance of Debt
597,000.00
597,000.00
1,025,000.00
--
1,895,000.00
Repayment of Debt
-424,000.00
-424,000.00
-546,000.00
-716,000.00
-416,000.00
Repurchase of Capital Stock
-40,000.00
-40,000.00
-42,000.00
-60,000.00
-106,000.00
Free Cash Flow
445,000.00
445,000.00
748,000.00
1,060,000.00
732,000.00
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
OXBDF Oxford Biomedica plc
5.27
0.00%
FTD.SG Financière de Tubize SA
150.40
-0.13%
ATBPF Antibe Therapeutics Inc.
0.2160
0.00%
TUB.BR Financière de Tubize SA
151.40
-0.13%
BOLD Boundless Bio, Inc.
2.4200
-3.20%
TECX Tectonic Therapeutic, Inc.
40.16
-8.46%
LXEO Lexeo Therapeutics, Inc.
6.39
-6.30%
TCRX TScan Therapeutics, Inc.
2.7700
-2.81%
22UA.F BioNTech SE
120.20
+1.52%
RLF.SW Relief Therapeutics Holding SA
3.8500
-1.53%